| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 60.11M | 64.83M | 76.35M | 99.50M | 105.62M | 78.01M |
| Gross Profit | 39.00M | 44.31M | 52.17M | 65.97M | 74.09M | 51.39M |
| EBITDA | -32.31M | -36.04M | -26.11M | -35.28M | -13.04M | -68.49M |
| Net Income | -41.34M | -47.00M | -37.25M | -43.58M | -23.01M | -82.82M |
Balance Sheet | ||||||
| Total Assets | 63.09M | 68.18M | 93.65M | 125.38M | 157.37M | 160.53M |
| Cash, Cash Equivalents and Short-Term Investments | 3.88M | 4.27M | 5.40M | 11.57M | 30.88M | 34.30M |
| Total Debt | 37.06M | 43.03M | 79.70M | 83.77M | 77.87M | 79.60M |
| Total Liabilities | 60.31M | 65.35M | 107.10M | 116.64M | 112.27M | 116.76M |
| Stockholders Equity | 2.33M | 2.37M | -14.02M | 8.09M | 40.94M | 44.23M |
Cash Flow | ||||||
| Free Cash Flow | -18.89M | -11.19M | -12.97M | -27.32M | -20.28M | -28.94M |
| Operating Cash Flow | -18.61M | -11.07M | -12.86M | -26.98M | -19.77M | -28.65M |
| Investing Cash Flow | -273.00K | -123.00K | -116.00K | -336.00K | -552.00K | -2.39M |
| Financing Cash Flow | 18.02M | 10.06M | 6.80M | 8.01M | 16.82M | 49.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $4.11M | -0.04 | -1371.21% | ― | -13.90% | 44.89% | |
45 Neutral | $8.95M | ― | -193.24% | ― | -66.40% | 65.99% | |
43 Neutral | $2.83M | -0.09 | ― | ― | -7.72% | 99.54% | |
42 Neutral | $11.65M | -0.33 | -195.48% | ― | -40.47% | 96.14% | |
40 Underperform | $7.00M | ― | -195.55% | ― | ― | 65.72% | |
37 Underperform | $29.94M | -0.01 | -101.49% | ― | -19.81% | 93.32% |
On September 30, 2025, Venus Concept Inc. completed a debt-to-equity exchange agreement with Madryn Health Partners, converting $11.48 million of subordinated convertible notes into 545,335 shares of Series Y preferred stock. This transaction reduced Venus Concept’s total debt by 24%, enhancing its financial position and supporting its strategic initiatives for long-term growth and profitability. The exchange agreement also involved amendments to existing loan agreements, providing additional financial flexibility and extending loan maturity dates.
The most recent analyst rating on (VERO) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
On September 19, 2025, Venus Concept Inc. secured a twelfth delayed drawdown of $2,000,000 under its Loan and Security Agreement with Madryn Health Partners, intended for general working capital. Additionally, the board approved transaction completion bonuses for executives Rajiv De Silva and Domenic Della Penna, contingent upon the successful completion of a strategic transaction involving a change of control.
The most recent analyst rating on (VERO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
On August 31, 2025, Venus Concept Inc. and its subsidiaries entered into several agreements with Madryn Health Partners to address liquidity requirements and loan maturity dates. The Consent Agreement waived certain minimum liquidity requirements under the MSLP Loan Agreement through September 30, 2025, while the Nineteenth Bridge Loan Amendment extended the maturity date of the Bridge Loan to September 30, 2025. Additionally, the Notes Consent Agreement waived liquidity requirements under the 2025 Notes, also through September 30, 2025. These agreements are aimed at providing financial relief and operational flexibility to Venus Concept Inc.
The most recent analyst rating on (VERO) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
Venus Concept’s recent earnings call painted a mixed picture of their financial health. The company showcased strategic achievements, such as sequential growth and a significant business sale, yet also faced ongoing challenges with revenue and profitability. While positive steps towards financial improvement were evident, significant issues remain, including revenue declines and increased losses.
Venus Concept Inc. announced the completion of its eleventh delayed drawdown under a Loan and Security Agreement with Madryn Health Partners, amounting to $2,000,000, on August 21, 2025. This funding is intended for general working capital purposes, reflecting the company’s ongoing efforts to secure financial stability and support its operations in the competitive medical aesthetics industry.
The most recent analyst rating on (VERO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.
Venus Concept Inc. is a global leader in medical aesthetic technology, offering a wide range of minimally invasive and non-invasive aesthetic and hair restoration technologies. In its second quarter of 2025, Venus Concept reported a total revenue of $15.7 million, reflecting a 5% decrease year-over-year but a 15% increase from the previous quarter. The company saw a 5% increase in U.S. revenue, driven by a 23% growth in cash systems sales. Despite these gains, the company reported a GAAP net loss of $11.7 million, an improvement from the $19.9 million loss in the same quarter last year. Additionally, the company completed several strategic financial transactions, including equity offerings and debt-to-equity exchanges, to strengthen its balance sheet. The sale of its Venus Hair business for $20 million is part of its strategy to focus on its core medical aesthetics business. Looking ahead, Venus Concept’s management remains focused on managing cash burn, enhancing its capital structure, and pursuing strategic initiatives to achieve long-term profitability.
On July 31, 2025, Venus Concept Inc. and its subsidiaries entered into several agreements with Madryn Health Partners to amend existing loan agreements, including waiving certain liquidity requirements and extending maturity dates. These amendments, including the Eighteenth Bridge Loan Amendment on August 6, 2025, aim to provide financial relief and operational flexibility, impacting the company’s financial strategy and stakeholder interests.
Venus Concept Inc. announced on July 21, 2025, the completion of its tenth delayed drawdown under a Loan and Security Agreement with Madryn Health Partners, securing an additional $2,000,000 in bridge financing. This funding, part of a larger $23,237,906.85 financing agreement, will be used for general working capital, reinforcing the company’s financial stability and operational capacity in the competitive medical aesthetics market.